- Home
- BLMN vs MNPR Comparison
BLMN vs MNPR Comparison
Compare BLMN & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLMN
- MNPR
- Stock Information
- Founded
- BLMN 1988
- MNPR 2014
- Country
- BLMN United States
- MNPR United States
- Employees
- BLMN N/A
- MNPR N/A
- Industry
- BLMN Restaurants
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- BLMN Consumer Discretionary
- MNPR Health Care
- Exchange
- BLMN Nasdaq
- MNPR Nasdaq
- Market Cap
- BLMN 576.9M
- MNPR 531.6M
- IPO Year
- BLMN 2012
- MNPR 2019
- Fundamental
- Price
- BLMN $6.95
- MNPR $89.67
- Analyst Decision
- BLMN Sell
- MNPR Strong Buy
- Analyst Count
- BLMN 7
- MNPR 13
- Target Price
- BLMN $8.29
- MNPR $97.83
- AVG Volume (30 Days)
- BLMN 2.5M
- MNPR 164.8K
- Earning Date
- BLMN 11-06-2025
- MNPR 11-13-2025
- Dividend Yield
- BLMN 10.01%
- MNPR N/A
- EPS Growth
- BLMN N/A
- MNPR N/A
- EPS
- BLMN N/A
- MNPR N/A
- Revenue
- BLMN $3,952,793,000.00
- MNPR N/A
- Revenue This Year
- BLMN $1.48
- MNPR N/A
- Revenue Next Year
- BLMN $1.40
- MNPR N/A
- P/E Ratio
- BLMN N/A
- MNPR N/A
- Revenue Growth
- BLMN 7.72
- MNPR N/A
- 52 Week Low
- BLMN $5.90
- MNPR $18.67
- 52 Week High
- BLMN $14.48
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- BLMN 52.65
- MNPR 57.29
- Support Level
- BLMN $5.90
- MNPR $74.58
- Resistance Level
- BLMN $6.47
- MNPR $100.50
- Average True Range (ATR)
- BLMN 0.45
- MNPR 7.61
- MACD
- BLMN 0.02
- MNPR 0.74
- Stochastic Oscillator
- BLMN 53.44
- MNPR 55.71
About BLMN Bloomin' Brands Inc.
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.